Healthcare Stocks

Another feather in Prescient Therapeutics’ (ASX:PTX) cap, bags new US Patent for PTX-100

 Another feather in Prescient Therapeutics’ (ASX:PTX) cap, bags new US Patent for PTX-100

Summary Prescient Therapeutics received new US Patent from the USPTO for companion diagnostic for PTX-100. It is another significant move for PTX in building a deep product pipeline of personalised targeted therapies and tools for treating canc...

Read More...
Prescient Therapeutics' Remarkable 2019 Journey

Prescient Therapeutics' Remarkable 2019 Journey

A clinical-stage Oncology company, Prescient Therapeutics Limited (ASX: PTX) is primarily engaged in developing novel personalized cancer therapies targeting an array of challenging cancers with significant unmet need. Prescient’s approach...

Read More...
Another Feather in Prescient’s Hat, Promising Efficacy Results from PTX-200 Phase 2a trial in HER2-Negative Breast Cancer

Another Feather in Prescient’s Hat, Promising Efficacy Results from PTX-200 Phase 2a trial in HER2-Negative Breast Cancer

Of late, clinical stage oncology company, Prescient Therapeutics (ASX: PTX), focused on developing personalized medicines with an approach to address mutations causing cancer, has been under the spotlight for recent advancements in its clinical trial...

Read More...
Prescient Takes Another Leap Forward, Unveils Promising Interim Results from PTX-200 Phase 1b Ovarian Cancer Trial

Prescient Takes Another Leap Forward, Unveils Promising Interim Results from PTX-200 Phase 1b Ovarian Cancer Trial

Clinical stage oncology company engaged in developing personalised medicine approaches including targeted and cellular therapies to beat cancer, Prescient Therapeutics (ASX: PTX) has been gaining industry limelight for its advancing clinical trials. ...

Read More...
Prescient Collaborates with Carina Biotech in Expansion into Exciting CAR-T Therapies

Prescient Collaborates with Carina Biotech in Expansion into Exciting CAR-T Therapies

Prescient Therapeutics Limited (ASX: PTX) develops personalised medicine approaches to address mutations that cause cancer. The Company employs a targeted therapy approach to target individual tumour variability rather than the conventional one size ...

Read More...
Prescient Unveils Encouraging Results: Eradication of Cancer in Three Acute Myeloid Leukemia Patients

Prescient Unveils Encouraging Results: Eradication of Cancer in Three Acute Myeloid Leukemia Patients

Clinical-stage Oncology Company, Prescient Therapeutics Limited (ASX: PTX), that develops personalised medicine approaches to address mutations causing cancer. Prescient?s deep product pipeline include 2 clinical stage drugs with multiple shots on go...

Read More...
A Walk-Through Prescient’s 2019 Achievements

A Walk-Through Prescient’s 2019 Achievements

Prescient Therapeutics Limited (ASX:?PTX) is involved in the development of breakthrough personalised cancer therapies via its novel anti-cancer drug candidates, PTX-100 and PTX-200, that have shown great promise in the treatment of a range of debili...

Read More...
Prescient Therapeutics Collaborates with Carina Biotech for Development of Next Generation CAR-T Therapies

Prescient Therapeutics Collaborates with Carina Biotech for Development of Next Generation CAR-T Therapies

Prescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company which is engaged in small molecule drug development focused on new cancer drugs. The company is known for having a robust clinical pipeline with two drug candidates, PTX ...

Read More...
Shedding light on the Recent Fuss about RAS, Prescient released AusBiotech Presentation

Shedding light on the Recent Fuss about RAS, Prescient released AusBiotech Presentation

With a focus on addressing mutations causing cancer, Prescient Therapeutics Limited (ASX:?PTX) develops personalised medicines as potential novel cancer remedies targeting an array of debilitating cancers with significant unmet need. ?Prescient has a...

Read More...
Prescient’s September 2019 Quarterly Update Unveils Encouraging Developments

Prescient’s September 2019 Quarterly Update Unveils Encouraging Developments

Prescient Therapeutics Limited (ASX:?PTX) is a clinical-stage oncology company focused on developing personalised medicines as potential novel targeted cancer therapies for a range of challenging cancers with significant unmet need. Prescient?s appro...

Read More...
Prescient’s Leaders Have A Rich History Of Taking Drugs From Bench To Bedside

Prescient’s Leaders Have A Rich History Of Taking Drugs From Bench To Bedside

Prescient Therapeutics Limited (ASX: PTX) is an Australian clinical stage oncology company that is into the development of personalised medicines for the treatment of multiple cancers. The company aims to develop novel drugs that work on the mechani...

Read More...
Ad

GET A FREE STOCK REPORT

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK